Latest Quarterly Sales News

ANO says Australian revenue from its Veganic sunscreen products fell 71% in the first quarter of FY27 after customer cancellations linked to media coverage and TGA involvement over product labelling. The company is preparing a legal claim against MooGoo, but no proceedings have yet been filed and the potential amount remains undisclosed.

The Calmer Co has secured an initial Coles order for its Fiji Kava FZZR Piña Colada 10-pack, with rollout expected across 583 stores from the week commencing 12 October. The launch comes as sales and supermarket distribution of the company’s existing kava range continue to expand.

EQ Resources has reported its second-highest quarterly production performance and record quarterly revenue, with cash on hand rising 192% to A$82.3 million. Both Barruecopardo and Mt Carbine increased output, although the update does not disclose operating costs or cash flow.

Eden Innovations reported a sharp acceleration in US sales during Q1 FY27, led by a 247% jump in OptiBlend revenue and expanding EdenCrete plant installations. The figures are unaudited management results, but they give the company a stronger opening quarter for the new financial year.

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.

OMG Group has reported its first positive quarterly EBITDA, with preliminary Q1 FY27 net sales rising 59% to approximately $1.92 million. The result marks a potential inflection point for the health and wellness food company, although the figures remain unaudited and do not establish cash profitability.

Alara Resources has shipped its 65th copper-concentrate parcel from Oman, closing out a record quarter with approximately 2,952 tonnes of contained copper sales. September’s total was 42% above the previous quarterly record and nearly double the comparable quarter a year earlier.

CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.

Freehill Mining’s Chilean aggregates operation reached record quarterly sales as the company moved deeper into copper-gold development. But the stronger operating performance came alongside a larger loss, negative operating cash flow and a material uncertainty over its ability to continue as a going concern.

FOS Capital anticipates a sharp earnings turnaround in FY27, driven by cost cuts, a $10 million order book, and a record $130 million pipeline.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Memphasys has cleared a key regulatory hurdle in Vietnam for its Felix™ System, prompting a significant first commercial cartridge order and marking early clinical success in a fast-growing fertility market.